Aripiprazole for the Treatment of Schizophrenia With Co-Morbid Social Anxiety
Status:
Completed
Trial end date:
2007-01-01
Target enrollment:
Participant gender:
Summary
This study will determine the efficacy of a medication switch to Aripiprazole for the
treatment of schizophrenia or schizoaffective disorder in patients with moderate to high
symptoms of social anxiety. Specifically the study will test the possibility that a
medication switch to Aripiprazole reduces symptoms of social anxiety in this patient
population.
Phase:
Phase 4
Details
Lead Sponsor:
University of Medicine and Dentistry of New Jersey